Brian Halbert, MD
Hematology & Oncology · New Orleans, LANPI 1003109364
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,170 of the $10,566 with a category attached, or 67.9%. 14 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 24.1% of the total. 2025 is the largest year on record at $7,512, more than ten times the $99 reported in 2022.
Across 58 payments — averaging $182.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$3K
- Eisai Inc.$3K
- Astellas Pharma US Inc$2K
- Johnson & Johnson$1K
- Bayer$933
- Exelixis Inc.$382
- plus $852 from 8 others
Across 2 payments — averaging $20,076 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$25K
- Merck$16K
What the payments were for
- Consulting fees$7,17068%
- Food & beverage$3,31631%
- Education$791%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 23 | $2,550 |
| Eisai Inc. | 2 | $2,504 |
| Astellas Pharma US Inc | 3 | $1,906 |
| Johnson & Johnson | 6 | $1,439 |
| Bayer | 3 | $933 |
| Exelixis Inc. | 3 | $382 |
| Pfizer | 4 | $337 |
| Myriad Genetic Laboratories, Inc. | 4 | $153 |
| Novartis | 3 | $126 |
| Sumitomo Pharma America, Inc. | 1 | $104 |
| Beone Medicines USA, Inc. | 2 | $40 |
| Beigene USA, Inc. | 2 | $38 |
| Progenics Pharmaceuticals, Inc. | 1 | $32 |
| Merck | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,566 in reported general payments places this provider in the 70th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 96 | $1,442,164 |
| CabometyxCabozantinib S-Malate | 46 | $1,183,945 |
| NubeqaDarolutamide | 89 | $1,158,010 |
| XtandiEnzalutamide | 39 | $530,631 |
| LenvimaLenvatinib Mesylate | 15 | $359,881 |
| Abiraterone Acetate | 233 | $141,899 |
| OrgovyxRelugolix | 37 | $93,685 |
| EliquisApixaban | 38 | $34,065 |
| MyrbetriqMirabegron | 27 | $12,230 |
| CreonLipase/Protease/Amylase | 11 | $8,594 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 19 | $1,093 |
| Prednisone | 317 | $1,074 |
| Prochlorperazine Maleate | 48 | $1,069 |
| Ondansetron Hcl | 44 | $835 |
| Oxycodone Hcl | 52 | $667 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $1,439 | $1,442,16496 claims |
| Exelixis Inc.Cabometyx | $382 | $1,183,94546 claims |
| BayerNubeqa | $933 | $1,158,01089 claims |
| Astellas Pharma US IncXtandi, Myrbetriq | $1,906 | $542,86166 claims |
| Eisai Inc.Lenvima | $2,504 | $359,88115 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $2,550 | $141,899233 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $104 | $93,68537 claims |
| PfizerEliquis | $337 | $34,06538 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in New Orleans
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Marc MatranaNew Orleans$757K
- Lingling duNew Orleans$173K
- Cindy LeissingerNew Orleans$135K
- Carter DavisNew Orleans$61K
- Furhan YunusNew Orleans$55K
- Michelle LochNew Orleans$50K
- David MorrisonNew Orleans$23K
- Scott SonnierNew Orleans$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.